ID 3089 - Bifidobacterium animalis ssp. lactis Bb-12

PL: Bifidobacterium animalis ssp. lactis Bb-12
EN: Bifidobacterium animalis ssp. lactis Bb-12
Pdf: Bifidobacterium animalis ssp. lactis Bb-12

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is Bifidobacterium animalis ssp. lactis Bb-12.
The species and strain identity and characteristics of Bifidobacterium animalis ssp. lactis Bb-12 (previously known as Bifidobacterium bifidum Bb-12, and also as Bifidobacterium lactis Bb-12, but subjected to reclassification) (Masco et al., 2004) have been determined using different genotypic methods (Garrigues et al., 2005; Mayer et al., 2007; Ventura et al., 2001a; Yimin et al., 1999, unpublished). It is important to point out that it may not be possible to differentiate commercially available Bifidobacterium animalis ssp. lactis strains from each other on the basis of traditional genetic methods (e.g. Pulsed Field Gel Electrophoresis) (Engel et al., 2003; Gueimonde et al., 2004), and that it may be necessary to use multi-locus sequencing or genome-wide approaches. The genome of Bifidobacterium animalis ssp. lactis Bb-12, although sequenced (Yimin et al., 1999, unpublished), was not publicly available at the time of the evaluation.
The deposit of the strain in the German culture collection DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) under number DSM 15954 was reported in the literature (Kajander et al., 2008). In addition, several authors consider the Bifidobacterium animalis ssp. lactis Bb-12 strain to be also equal to the strain DSMZ 10140 (Ventura et al., 2001b). This view is due to the fact that, although the strain owner did not deposit the strain under the Bifidobacterium animalis ssp. lactis Bb-12 name, strain DSMZ 10140 was isolated from a yoghurt containing Bifidobacterium animalis ssp. lactis Bb-12 which was deposited by Meile et al. (1997).
The Panel considers that the food constituent, Bifidobacterium animalis ssp. lactis Bb-12, which is the subject of the health claims, is sufficiently characterised.

2.5. Utrzymanie prawidłowego stężenia cholesterolu LDL we krwi (ID 3089)

The claimed effect is “maintain normal cholesterol”. The Panel assumes that the target population is the general population.
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the normal structure and function of the arteries.
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect.

3.3. Utrzymanie prawidłowego stężenia cholesterolu LDL we krwi (ID 3089)

None of the references provided for the scientific substantiation of the claim addressed the strain Bifidobacterium animalis ssp. lactis Bb-12, which is the subject of the claim. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claimed effect.
The Panel concludes that a cause and effect relationship has not been established between the consumption of Bifidobacterium animalis ssp. lactis Bb-12 and maintenance of normal blood LDL- cholesterol concentrations.

Warunki i możliwe ograniczenia stosowania oświadczenia

1.0 x 10 [8] cfu